Novel combinations of DNMTs and PARP inhibitors could enhance effectiveness; for example, AML patients which are resistant to chemotherapy are treated with a novel combination therapeutic strategy that is more effective when combined with decitabine (DNMT inhibitors) [216]. Here, PARP1 is linked to acute myeloid leukemia.